A cluster of attention-grabbing announcements from ASX-listed biotech juniors this morning touched on several key pressure points for the sector — clinical timelines, regulatory clearance, scientific credibility and US trial execution.
Updates from Racura Oncology, Memphasys, Noxopharm and Amplia Therapeutics cover noteworthy advancements including trial protocol amendments designed to pull forward key data, Australian regulatory clearance for a key product, high-impact scientific publication and the expansion of US trial sites in pancreatic cancer.
The session underscores the steady flow of operational and regulatory milestones shaping the ASX biotech landscape this year, from early mechanistic validation to commercial rollouts and international trial expansion. Here’s a closer look at the details.
Racura adds new blood test to CPACS trial
Racura Oncology Ltd (ASX:RAC, FRA:FN3) announced that it has amended its RAC-010 cardioprotection and anticancer synergy (CPACS) trial to incorporate a newly developed blood-based molecular test designed to assess the cardioprotective effects of RC220.
The assay is based on Racura’s recently identified mechanism of action for (E,E)-bisantrene and will be used to analyse patient samples from doxorubicin-treated participants. The goal is to quantify whether RC220 protects the molecular pathways responsible for anthracycline-induced cardiotoxicity.
Crucially, the company believes the test could provide early clinical and scientific cardioprotection data more than two years ahead of the original schedule.
To enable this, Racura modified the trial protocol to include an initial cycle of doxorubicin monotherapy to establish a molecular baseline. Implementing the change required approvals across Australia, Hong Kong and South Korea, a process that took around six months.
Recruitment slowed during the transition but has recently picked up, with three patients now in pre-screening and Australian sites cleared under the amended protocol. Offshore approvals are expected in the coming weeks.
Memphasys secures TGA approval for Felix™
Memphasys Ltd (ASX:MEM) announced that its Felix™ sperm separation system has received approval from the Therapeutic Goods Administration and has been included on the Australian Register of Therapeutic Goods.
The approval arrived about two months ahead of the company’s previously guided timeframe, allowing immediate commercial sale and clinical deployment across Australia.
Felix is designed to isolate viable sperm cells using electrophoresis and size-exclusion membranes, offering an alternative to traditional centrifugation techniques used in IVF laboratories.
With more than 60,000 fresh IVF cycles performed annually in Australia, the domestic market represents a defined opportunity. The earlier clearance allows Memphasys to transition from pre-commercial readiness into active deployment, with a strategy focused on installing Felix™ systems and generating recurring revenue through per-procedure cartridge sales.
Noxopharm’s Sofra science published in Nature Immunology
Noxopharm Ltd (ASX:NOX) reported that the scientific research underpinning its Sofra™ platform has been published in Nature Immunology, a leading peer-reviewed journal in immunology.
The paper details a newly identified anti-inflammatory mechanism involving 2′-O-methyl-guanosine RNA fragments that antagonise immune sensors TLR7 and TLR8, limiting inappropriate immune activation and autoimmunity.
The research was led by Professor Michael Gantier of the Hudson Institute of Medical Research, Noxopharm’s strategic partner in developing the technology, with contributions from multiple international research institutions.
For Noxopharm, the publication provides independent scientific validation of the biological mechanism underlying its platform, which is being developed for inflammatory and autoimmune diseases, including SOF-SKN™.
Amplia opens US sites for AMPLICITY trial
Amplia Therapeutics Ltd (ASX:ATX) announced that two US sites — the University of California, Irvine and the Cleveland Clinic — have completed initiation activities and will begin recruitment for the AMPLICITY pancreatic cancer trial.
They join two sites already open in Australia, with three additional US centres expected to follow shortly.
AMPLICTY is investigating narmafotinib, Amplia’s focal adhesion kinase (FAK) inhibitor, in combination with modified FOLFIRINOX in newly diagnosed patients with advanced pancreatic cancer. The study is being conducted under an open Investigational New Drug application with the US FDA.
Expanding the US footprint increases the potential patient pool and should support ongoing enrolment as the trial progresses through its dose-finding and optimisation phases.